Roche has put forward a new approach to genetic analysis, which it describes as sequencing-by-expansion—a proprietary method that pulls apart the DNA molecule and amplifies the signal of each ...

L’Oreal has recalled all U.S. lots of La Roche-Posay’s Effaclar Duo acne treatment due to concerns over benzene contamination, a known carcinogen. Benzoyl peroxide, a key ingredient in ...

Belgian anti-trust regulators are probing Roche over concerns that the drug company took steps to delay the entry of biosimilar versions of two of its cancer medicines. In a brief statement ...

Swiss pharmaceutical company Roche announced Friday it will open an innovation center in the Harvard University Enterprise Research Campus in Allston that could employ hundreds. The Roche ...

Here's why La Roche-Posay is pulling its Effaclar Duo Acne Spot Treatment from retail shelves. La Roche-Posay is a brand under the L'Oreal Group umbrella. A La Roche-Posay spokesperson confirmed ...

Novo Nordisk’s NVO stock declined 4.3% on Wednesday after Roche RHHBY announced a license and collaboration deal worth $5.3 billion with Denmark’s Zealand Pharma to co-develop its lead obesity ...

A multinational healthcare company, Roche and a provider of digital integrated healthcare services, Oncopadi Technologies have launched a Breast Cancer Access Navigation and Testing Programme ...

Roche is expanding its scope to a promising but competitive new obesity target, committing $1.65 billion up front to partner on a clinical-stage Zealand Pharma molecule with the potential to be a ...

Swiss pharmaceutical giant Roche said Wednesday that it had struck a deal worth up to $5.3 billion to develop Danish biotech Zealand Pharma's obesity drug candidate, as the two firms seek to ...

But those days had settled down. Or so we thought. This week, Roche made it feel like 2022 again. Just days before the AGBT meeting kicks off in Marco Island, FL, the company hosted a much ...

Roche is paying $1.65 billion in confirmed upfront fees to add to its burgeoning obesity pipeline. The outlay, plus up to $3.6 billion in milestones, has secured Roche the right to codevelop and ...

Novo Nordisk’s U.S.-listed shares slumped 4.5%, while Eli Lilly lost 1.2% as of 10:57 GMT. Under the agreement, Roche will pay Zealand $1.65 billion upfront, with additional milestone payments ...